Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
MWN-AI** Summary
Corcept Therapeutics (NASDAQ: CORT) recently presented compelling data from its MOMENTUM trial at the American College of Cardiology Annual Scientific Session (ACC 2026). This study aimed to evaluate the prevalence of endogenous hypercortisolism in patients suffering from resistant hypertension. Screening over 1,000 patients, the trial revealed that 27.3% (297 patients) exhibited hypercortisolism, highlighting a significant health concern within this demographic.
This new finding aligns with data from Corcept's earlier CATALYST trial, which indicated hypercortisolism in 23.8% of patients diagnosed with difficult-to-treat type 2 diabetes. Specifically, in the MOMENTUM trial, patients with a hemoglobin A1c of 7.5% or greater who were on three or more blood pressure medications had a hypercortisolism prevalence of 32.6%. In comparison, CATALYST showed a prevalence of 36.6% in a similar cohort.
Dr. Deepak L. Bhatt, a key investigator in the MOMENTUM trial, emphasized the importance of these findings, stating that hypercortisolism contributes significantly to resistant hypertension, presenting an opportunity for healthcare providers to personalize treatment strategies through screening. Highlighting the critical nature of this disorder, Dr. Bhatt noted that resistant hypertension is associated with severe cardiovascular risks.
Corcept's Chief Development Officer, Bill Guyer, underscored the broader implications of the findings, advocating for increased screening for hypercortisolism to improve diagnostic accuracy and treatment options. With MOMENTUM being the largest US-based study to assess this issue, it marks a pivotal moment in hypertension management.
Corcept Therapeutics continues its mission to leverage cortisol modulation in treating serious health conditions, with ongoing clinical trials exploring a range of disorders from Cushing's syndrome to various cancers.
MWN-AI** Analysis
Corcept Therapeutics (NASDAQ: CORT) has recently presented notable findings from its MOMENTUM trial at the 2026 American College of Cardiology Annual Scientific Session. The study revealed that 27.3% of patients with resistant hypertension exhibited hypercortisolism, highlighting a significant oversight in managing this challenging condition. These findings align with prior results from the CATALYST trial, which affirmed the prevalence of hypercortisolism in patients with type 2 diabetes, a critical insight suggesting a wider indication for testing among patients who are resistant to conventional blood pressure treatments.
The implications for Corcept are substantial. As awareness increases regarding the role of hypercortisolism in cardiovascular diseases, the company could see enhanced demand for its therapies, particularly Korlym® and Lifyorli™. In fact, the data not only supports Corcept's existing product lines but also provides a strong argument for expanded screening protocols in clinical practice. This could lead to broader adoption of their products among healthcare providers aiming to improve patient outcomes in resistant hypertension and related disorders.
Investors should view this data as a positive sign of potential growth, particularly considering Corcept's focus on corticosteroid modulation—a field that may garner increased attention from healthcare systems seeking more effective management strategies for hypertension-related issues. Additionally, the timing of the presentation, coupled with the central role of prominent figures in cardiovascular medicine in the study, enhances Corcept's credibility and position within the field.
As Corcept expands its research and product offerings, its stock may gain traction amid heightened interest from both clinical and investor communities. Overall, this emerging landscape emphasizes the need for investors to stay attuned to developments in adrenal suppression therapies, as Corcept could be poised for significant gains as a transformative player in this sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Hypercortisolism identified in 27.3 percent of patients with resistant hypertension
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented late-breaking data from its MOMENTUM trial examining the prevalence of endogenous hypercortisolism in patients with resistant hypertension at the 2026 American College of Cardiology Annual Scientific Session (ACC 2026).
MOMENTUM screened 1,086 patients with resistant hypertension (as defined by the American Heart Association’s criteria ) and found that 27.3 percent, or 297 patients had hypercortisolism. This finding complements the results of Corcept’s CATALYST trial, which found hypercortisolism in 23.8 percent of the 1,057 patients screened with difficult-to-control type 2 diabetes. The prevalence of hypercortisolism in patients who had hemoglobin A1c (HbA1c) of 7.5 percent or higher and were taking 3 or more blood pressure medicines was 32.6 percent in MOMENTUM and 36.6 percent in CATALYST.
“Resistant hypertension increases the risk of cardiovascular events like heart attacks, strokes, and heart failure, as well as kidney damage,” said Deepak L. Bhatt, M.D., M.P.H., M.B.A., Director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai. “MOMENTUM shows that hypercortisolism contributes to resistant hypertension in over a quarter of patients and that screening for hypercortisolism in these challenging-to-treat patients may help physicians provide more personalized care.” Dr. Bhatt presented the data as Featured Clinical Research at ACC 2026, is a lead investigator and steering committee member for MOMENTUM, and a paid consultant to Corcept Therapeutics.
“It is now clear that hypercortisolism is more common than previously assumed in patients whose hypertension and diabetes don’t respond to standard-of-care treatments,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer. “We are grateful to the investigators and patients who have participated in this research and hope that the findings will provide critical information to support increased screening for hypercortisolism, more accurate diagnoses and improved treatment options.”
About MOMENTUM
MOMENTUM was the largest US-based trial ever conducted to assess the prevalence of hypercortisolism in patients with resistant hypertension. A total of 1,086 patients were screened at 50 sites across the United States. All patients had resistant hypertension as defined by the American Heart Association’s criteria (systolic blood pressure greater or equal to 130 mmHg despite taking 3 or more blood-pressure lowering medications, including a diuretic, or taking 4 or more blood-pressure lowering medications). Using a simple, standardized 1-mg dexamethasone suppression test (DST), 27 percent of these patients were found to have hypercortisolism.
About Hypercortisolism
Hypercortisolism, also known as Cushing’s syndrome, is caused by excessive activity of the hormone cortisol. Symptoms vary, but most patients experience one or more of the following manifestations: hypertension, central obesity, elevated blood sugar and difficult-to-control type 2 diabetes, severe fatigue and weak muscles. Irritability, anxiety, depression and cognitive disturbances are common. Hypercortisolism can affect every organ system and can be fatal if not treated effectively. Cardiovascular events are the most common cause of death. Recent research shows that endogenous hypercortisolism is more prevalent than previously believed.
About Corcept Therapeutics
For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders, leading to the discovery of more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with Cushing’s syndrome, solid tumors, ALS and liver disease. In 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with endogenous Cushing’s syndrome, and in 2026, the company introduced Lifyorli™, approved in combination with nab-paclitaxel, the first FDA-approved selective glucocorticoid receptor antagonist for adults with platinum-resistant ovarian cancer. Corcept is headquartered in Redwood City, California. For more information, visit Corcept.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20260328971109/en/
Investor inquiries:
ir@corcept.com
Media inquiries:
communications@corcept.com
www.corcept.com
FAQ**
How does the recent data from Corcept Therapeutics Incorporated (CORT) on hypercortisolism impact the company's overall strategy in treating resistant hypertension and type 2 diabetes?
What role does Corcept Therapeutics Incorporated (CORT) envision for their cortisol modulators in light of the findings from the MOMENTUM trial regarding the prevalence of hypercortisolism?
Given the findings of the MOMENTUM trial presented by Corcept Therapeutics Incorporated (CORT), how might the company address the potential for increased demand in screening and treating hypercortisolism?
How does Corcept Therapeutics Incorporated (CORT) plan to leverage the results from the CATALYST trial alongside the MOMENTUM trial to enhance its clinical development pipeline?
**MWN-AI FAQ is based on asking OpenAI questions about Corcept Therapeutics Incorporated (NASDAQ: CORT).
NASDAQ: CORT
CORT Trading
-1.48% G/L:
$38.18 Last:
611,552 Volume:
$38.09 Open:
